These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 36572913)

  • 1. Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials.
    Wu S; Lu W; Chen Z; Dai Y; Chen K; Zhang S
    Diabetol Metab Syndr; 2022 Dec; 14(1):195. PubMed ID: 36572913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
    He L; Wang J; Ping F; Yang N; Huang J; Li Y; Xu L; Li W; Zhang H
    JAMA Intern Med; 2022 May; 182(5):513-519. PubMed ID: 35344001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials.
    Li W; Chen X; Xie X; Xu M; Xu L; Liu P; Luo B
    J Cardiovasc Pharmacol; 2022 Mar; 79(3):281-288. PubMed ID: 34935705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of cardiovascular outcome trials assessing the impact of glucagon-like peptide-1 receptor agonists on major cardiac arrhythmias.
    Boulmpou A; Patoulias D; Papadopoulos CE; Teperikidis E; Doumas M; Vassilikos V
    Acta Cardiol; 2023 Jul; 78(5):519-524. PubMed ID: 35699112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: A systematic review and meta-analysis.
    Wei J; Wang R; Ye H; Wang Y; Wang L; Zhang X
    Front Endocrinol (Lausanne); 2022; 13():910256. PubMed ID: 36034440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction.
    Liu Z; Bian N; Wu S; Fan Y; Li H; Yu J; Guo J; Chen D
    Front Cardiovasc Med; 2022; 9():1019120. PubMed ID: 36277800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular Benefits of GLP-1 Receptor Agonists in Patients Living with Obesity or Overweight: A Meta-analysis of Randomized Controlled Trials.
    de Oliveira Almeida G; Nienkötter TF; Balieiro CCA; Pasqualotto E; Cintra JB; Carvalho HCP; Silva ALS; Kabariti JC; Minucci BS; Bertoli ED; Guida CM
    Am J Cardiovasc Drugs; 2024 Jul; 24(4):509-521. PubMed ID: 38734847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials.
    Zhang YS; Weng WY; Xie BC; Meng Y; Hao YH; Liang YM; Zhou ZK
    Osteoporos Int; 2018 Dec; 29(12):2639-2644. PubMed ID: 30083774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
    Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
    Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta-analysis.
    Saglietto A; Falasconi G; Penela D; Francia P; Sau A; Ng FS; Dusi V; Castagno D; Gaita F; Berruezo A; De Ferrari GM; Anselmino M
    Eur J Clin Invest; 2024 Jul; ():e14292. PubMed ID: 39058274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials.
    Wu S; Sun F; Zhang Y; Yang Z; Hong T; Chen Y; Zhan S
    J Clin Pharm Ther; 2014 Feb; 39(1):7-13. PubMed ID: 24127768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.
    Li WX; Gou JF; Tian JH; Yan X; Yang L
    Curr Ther Res Clin Exp; 2010 Aug; 71(4):211-38. PubMed ID: 24688145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials.
    Hu W; Song R; Cheng R; Liu C; Guo R; Tang W; Zhang J; Zhao Q; Li X; Liu J
    Front Endocrinol (Lausanne); 2022; 13():927859. PubMed ID: 35898463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials.
    Yu M; Wang R; Pei L; Zhang X; Wei J; Wen Y; Liu H; Ye H; Wang J; Wang L
    Diabetol Metab Syndr; 2023 Jul; 15(1):164. PubMed ID: 37491292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.
    Qin J; Song L
    BMC Endocr Disord; 2022 May; 22(1):125. PubMed ID: 35546664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 receptor agonists and stroke: A systematic review and meta-analysis of cardiovascular outcome trials.
    Adamou A; Barkas F; Milionis H; Ntaios G
    Int J Stroke; 2024 Oct; 19(8):876-887. PubMed ID: 38676552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semaglutide for the prevention of atrial fibrillation: A systematic review and meta-analysis.
    Zhang HD; Ding L; Liu K; Mi LJ; Zhang AK; Yu FY; Yan XX; Peng FH; Shen YJ; Tang M
    Diabetes Metab Syndr; 2024 Jun; 18(6):103067. PubMed ID: 38955095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of GLP-1 Agonists on mortality and arrhythmias in patients with Type II diabetes.
    Al-Sadawi MA; Aslam FM; Tao M; Alsaiqali M; Almasry IO; Fan R; Rashba EJ; Singh A
    Int J Cardiol Heart Vasc; 2023 Aug; 47():101218. PubMed ID: 37252197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of > 80,000 patients (the SGLT2i-Arrhythmias and Sudden Cardiac Death).
    Liao J; Ebrahimi R; Ling Z; Meyer C; Martinek M; Sommer P; Futyma P; Di Vece D; Schratter A; Acou WJ; Zhu L; Kiuchi MG; Liu S; Yin Y; Pürerfellner H; Templin C; Chen S
    Cardiovasc Diabetol; 2024 Feb; 23(1):78. PubMed ID: 38402177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.